Ozuriftamab BA302 represents a remarkable advancement in tumor therapy. This unique antibody-drug conjugate specifically targets the BCMA protein, a essential protein expressed on multiple myeloma cells and some lymphoma types. Its process of action involves delivering a potent payload directl

Emicizumab, designated vonWil is representing a significant development in hemophilia bleeding condition . This groundbreaking factor functions as a prothrombin precursor , substituting for factor VIII, a component often missing in people with types of hemophilia . Unlike traditional factor thera

Carotuximab, identified as TRC105 or DE-122, represents a emerging antibody-drug conjugate therapeutic currently evaluated for treating various malignant diseases. This particular molecule targets a defined antigen, expressed on tumor cells,

Vadastuximab disitamab vedotin antibody-drug compound representing a important advancement in the treatment of acute myeloid leukemia (AML). This groundbreaking therapy precisely targets CD33, a antigen frequently found on leukemic blasts . The process involves binding to CD33, causing both cellu

The introduction of amivantamab offers a significant advance for individuals battling cancers featuring c-MET aberration. This unique antibody, a precise blocker of dual MET kinase and also human epidermal growth factor receptor 2 (HER2), demonstrated early results in clinical trials, particularl